Latest Chronic kidney disease Stories
- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome - LA JOLLA, Calif.,
Phase 2 clinical trial of VPI-2690B will enroll patients with kidney damage due to type 1 or type 2 diabetes at multiple centers throughout the United States. Chapel
Most Nephrologists Believe There Is Some Level of Unmet Need for ESAs in CKD-ND and Dialysis Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
NxStage and Chronic Disease Research Group Announce Study at the American Society of Nephrology's Kidney Week 2014 LAWRENCE, Mass., Nov.
Illinois home hemodialysis nurse honored for exceptional dedication to patients LAWRENCE, Mass., Nov. 4, 2014 /PRNewswire/ -- NxStage® Medical, Inc.
CALGARY, Nov. 3, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development. Dr.
Products in DN Development are Most Likely to be Used in Stage 3 CKD, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Company shares resources to help individuals with diabetes assess their risk for kidney disease DENVER, Nov.
STOCKHOLM, November 3, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces that clinical results from the initial
- The act of lurking; skulking about; hiding; keeping from sight.